Carlsson et al. (2000) Network Interactions in Schizophrenia (Edexcel A-Level Psychology): Revision Notes

Carlsson et al. (2000) Network Interactions in Schizophrenia

Theorist, title, year

Arvid Carlsson et al. (2000) - "Network interactions in schizophrenia - therapeutic implications"

Aim

This review article examined research exploring the relationship between neurotransmitter levels and schizophrenia symptoms, with particular focus on dopamine and glutamate. The researchers identified two competing theoretical positions regarding neurochemical explanations for schizophrenia:

• Hyperdopaminergia: The theory proposing that elevated dopamine levels cause schizophrenia symptoms
• Hypoglutamatergia: The theory suggesting that reduced glutamate levels contribute to the disorder

The review aimed to assess whether drugs that modify brain chemistry could provide more effective treatments for schizophrenia. At the time, existing antipsychotic medications primarily reduced dopamine levels but were ineffective for many patients and caused problematic side effects. The researchers sought to determine whether other neurotransmitters might be implicated in the disorder, potentially opening new avenues for treatment development.

Procedure

Carlsson et al. conducted a comprehensive literature review of existing research, examining evidence from multiple sources:

Evidence reviewed

Brain scan studies: The review included neuroimaging research, such as PET scans from Abi-Dargham et al. (1998) and Breier et al. (1997), which provided objective measurements of dopamine levels in patients diagnosed with schizophrenia. These studies had established that elevated dopamine concentrations were associated with psychotic symptoms.

Recreational drug research: The researchers examined studies investigating drugs known to induce psychosis in users. This included:

• Research linking amphetamines (which increase dopamine levels) to schizophrenia symptoms
• Studies on phencyclidine (PCP or 'Angel dust'), which increases dopamine levels but also affects other neurotransmitter systems

Antipsychotic medication studies: The review analysed research into drug treatments for schizophrenia, examining both their mechanisms of action and their effectiveness. Particular attention was paid to how different medications affect neurotransmitter systems in the brain.

Dopamine-glutamate interaction research: Evidence was gathered on the relationship between dopamine and glutamate production, exploring how reduced glutamate levels might influence dopamine release.

Findings

Role of glutamate

The review found substantial research evidence supporting the involvement of low glutamate levels in the development of psychotic symptoms. Specifically:

Phencyclidine (PCP) functions as an antagonist of NMDA receptors, a specific glutamate receptor subtype. This means PCP inhibits glutamate's action in certain brain regions. Users of PCP were found to be more likely to experience psychosis than even amphetamine users, despite previous research having focused primarily on amphetamines' dopamine-increasing effects.

Brain region specificity

Carlsson et al. noted that glutamate dysfunction in different brain areas was associated with different symptom types:

• Cerebral cortex (the outer layer of the brain): Glutamate failure in this region may lead to negative symptoms of schizophrenia, such as social withdrawal, lack of motivation, and flattened emotional responses.

• Basal ganglia (structures at the brain's base involved in movement coordination): Glutamatergic failure in these structures could be responsible for positive symptoms, including hallucinations, delusions, and disordered thinking.

Treatment implications

The review highlighted clozapine as a particularly effective antipsychotic medication, producing fewer reported negative side effects compared to other treatments. Clozapine has been shown to work in patients who previously failed to respond to alternative medications.

Clozapine's effectiveness may stem from its dual action:

• Antidopaminergic properties (blocking dopamine activity)
• Antiserotonerergic properties (blocking serotonin activity)

The relationship between serotonin and glutamate suggested that this dual-action mechanism could explain why some patients with schizophrenia, who may better fit a hypoglutamatergia profile, respond to clozapine when other treatments fail.

Conclusion drawn

The researchers concluded that schizophrenia may comprise different subtypes caused by abnormal levels of various neurotransmitters, not solely dopamine. This would explain why not all patients respond to dopamine-reducing medications. They emphasised the need for continued research into drugs that reduce relapse rates whilst minimising negative side effects, potentially by targeting multiple neurotransmitter systems simultaneously. Newer drug compounds in development at the time aimed to reduce dopamine levels without causing the extremely low dopamine concentrations associated with side effects such as tremors.

Evaluation: Strengths

Comprehensive data synthesis

The review's reliance on secondary data from numerous different studies provided several advantages. Rather than conducting a single, time-limited investigation, Carlsson et al. were able to draw together evidence from multiple research teams using various methodologies. This approach allowed them to identify patterns across different studies and build a more complete picture of neurochemical involvement in schizophrenia than any single study could provide.

Objective measurement techniques

Much of the evidence reviewed came from highly reliable research methods, particularly PET scans and other neuroimaging techniques. These provide objective, quantifiable measurements of neurotransmitter activity in different brain regions. Brain scanning technology offers a strong evidence base for biological explanations of mental health conditions because it directly measures brain chemistry and activity rather than relying on subjective reports.

Scientific rigour

The evidence cited focused on scientific methodology employing precise measurement techniques. This approach aligns with psychology's status as a science, using empirical data to build understanding of behaviour and mental processes. The biological basis demonstrated through such research strengthens the validity of neurochemical explanations for schizophrenia.

Clinical applications

The review's findings have direct practical implications for treatment development. By suggesting that different patients may have different neurochemical profiles, the research opened pathways for more personalised medication approaches. The identification of clozapine's dual-action mechanism provided insight into why this drug succeeds where others fail, potentially guiding future drug development.

Evaluation: Weaknesses

Reliability concerns with secondary data

Whilst gathering evidence from multiple sources increased the breadth of information available, it introduced methodological challenges. The researchers had no way of verifying the validity or reliability of the original studies they reviewed. Questions about how well each study was conducted, whether appropriate research procedures were followed, or whether any single study could be trusted remain unanswered. Basing therapeutic conclusions on potentially problematic research could be concerning when those conclusions influence actual treatment approaches.

Time and resource implications

Although the review synthesised existing evidence efficiently, the original studies cited would have required enormous amounts of time and resources to conduct. Gathering such comprehensive evidence firsthand would be prohibitively expensive and time-consuming. This highlights a practical limitation: whilst secondary research provides a broad overview quickly, truly verifying the core findings would demand substantial investment that may not be feasible.

Lack of unified methodology

The reviewed studies employed different research designs, participant samples, and measurement techniques. This heterogeneity makes it difficult to draw definitive conclusions because variations between studies might account for different results. The review article format meant that Carlsson et al. were not following a standard research procedure such as those used in AFRC (Association for the Promotion of Research in Clinical Psychology) approved studies, which could limit the certainty of their conclusions.

Treatment development challenges

The review identified that many antipsychotic medications are currently ineffective for a substantial proportion of patients, and those that do work often take considerable time to show effects. For some individuals, effective treatment never materialises. Whilst the research suggests newer approaches targeting multiple neurotransmitter systems might address this issue, translating these findings into practical, widely available treatments remains a significant challenge.

Key terms

Glutamate: A neurotransmitter involved in activating neurones and enabling neural transmission. In the context of schizophrenia, low levels may be associated with psychotic symptoms.

Dopamine: A neurotransmitter traditionally linked to schizophrenia through the hyperdopaminergia hypothesis, which proposes that excessive dopamine activity contributes to positive symptoms.

Hyperdopaminergia: Elevated levels of dopamine in the brain, historically considered the primary neurochemical explanation for schizophrenia.

Hypoglutamatergia: Reduced levels of glutamate, an alternative neurochemical explanation for schizophrenia proposed as a counterpoint to the dopamine hypothesis.

Phencyclidine (PCP): Originally developed as an anaesthetic, this drug induces numbness but is no longer used medically due to other effects including hallucinations, reality distortion, and mood changes. PCP blocks NMDA receptors, inhibiting glutamate action.

NMDA receptors: A specific subtype of glutamate receptors that PCP antagonises, reducing glutamate activity in affected brain regions.

Cerebral cortex: The outer layer of the brain where glutamate failure may produce negative symptoms of schizophrenia.

Basal ganglia: Brain structures located at the base of the brain, associated with movement coordination. Glutamatergic failure here may cause positive symptoms.

Antidopaminergic: A property of drugs that block or reduce dopamine activity in the brain.

Antiserotonerergic: A property of drugs that block or reduce serotonin activity in the brain.

Clozapine: An antipsychotic medication effective for treatment-resistant patients, possessing both antidopaminergic and antiserotonerergic properties.

Remember!